A New Lung Cancer Immunotherapy Combination Just Beat a PD-1 Inhibitor Head-to-Head: What HARMONi-6 Found

At the 2026 ASCO Annual Meeting plenary session, a Phase 3 trial called HARMONi-6 delivered one of the more striking head-to-head immunotherapy results in recent memory: a bispecific antibody called ivonescimab, combined with chemotherapy, extended median survival by roughly four months compared with a leading PD-1 checkpoint inhibitor plus the same chemotherapy, in patients with advanced squamous non-small cell lung cancer (NSCLC). This article covers what the trial found, why the mechanism is genuinely novel, and the important caveats — including where it was conducted and where it isn't yet approved.

The Trial, in Plain Terms

HARMONi-6 enrolled 532 patients with advanced (stage IIIB–IV) squamous NSCLC who had not yet received treatment and did not have EGFR or ALK mutations. Roughly half received ivonescimab plus carboplatin and paclitaxel chemotherapy; the other half received tislelizumab, a PD-1 checkpoint inhibitor, plus the same chemotherapy backbone. Both groups received treatment every three weeks for up to four cycles, followed by up to 24 months of maintenance therapy. The trial was conducted in China by Akeso, with Summit Therapeutics holding U.S. and other ex-China development rights.

The Survival Numbers Are the Headline — And They're Genuinely Good

This is where the news is worth letting breathe: patients on ivonescimab plus chemotherapy had a median overall survival of 27.89 months, compared with 23.89 months for those on the PD-1 inhibitor plus chemotherapy — a difference of roughly four months in the median, and a hazard ratio of 0.66 (p=0.0017), meaning a statistically significant reduction in the risk of death favoring ivonescimab. Progression-free survival, an earlier readout, also favored ivonescimab substantially: a median of 11.1 months versus 6.9 months in an interim analysis. For a head-to-head trial against an active PD-1 comparator — not a placebo — a hazard ratio this strong is a notable result in lung cancer immunotherapy.

What Makes Ivonescimab Different

Ivonescimab is a bispecific antibody, meaning it's engineered to bind two separate targets at once: PD-1, the same checkpoint protein blocked by drugs like pembrolizumab and tislelizumab, and VEGF, a protein that promotes tumor blood vessel growth. The idea is that blocking both pathways simultaneously — reawakening the immune system's attack on the tumor while also cutting off its blood supply — could outperform blocking PD-1 alone. HARMONi-6 is the first Phase 3 trial to test that combined-mechanism hypothesis directly against a standard PD-1 inhibitor rather than against chemotherapy alone, which is what makes the result scientifically meaningful rather than just incrementally better.

The Trade-Offs: A More Active Drug Came With More Side Effects

In keeping with real, unhedged reporting: the survival benefit came with a higher rate of serious toxicity. Grade 3 or higher treatment-related adverse events occurred in 69.2% of patients on ivonescimab versus 58.9% on tislelizumab. Treatment-related deaths were similar between arms (3.8% versus 4.2%), but the higher overall serious-adverse-event rate is a real clinical trade-off, not a footnote, and it's the kind of finding regulators and oncologists will weigh carefully against the survival gain.

Where This Stands, Regulatory-Wise

Ivonescimab has been approved in China since 2024, and HARMONi-6 was conducted entirely in Chinese trial sites. As of this writing, ivonescimab does not have FDA approval in the United States. The interim overall survival results were presented at the 2026 ASCO Annual Meeting plenary session and have since been published as a peer-reviewed paper in The Lancet — real, published evidence, not just a conference abstract. Summit Therapeutics has other ivonescimab trials underway to support a U.S. regulatory filing, but a single positive Phase 3 trial from one country's health system, however well-designed and well-published, is not the same thing as an approved U.S. treatment option.

What It Means for Patients Right Now

For patients and clinicians in the U.S., HARMONi-6 doesn't change today's standard of care — pembrolizumab- and other PD-1/PD-L1-based regimens remain the approved options for advanced squamous NSCLC. What it does signal is a plausible next generation of lung cancer immunotherapy built on dual-mechanism antibodies, and it strengthens the case for additional bispecific trials now underway globally, including ones enrolling U.S. patients.

Bottom Line

HARMONi-6 is a genuinely encouraging result: a four-month median survival advantage against an active comparator, with a strong hazard ratio, in one of the hardest-to-treat lung cancer subtypes, published in The Lancet. It deserves to be reported as good news. But it's one trial, run in one country's regulatory system, with a real increase in serious side effects and no U.S. approval yet. Patients with advanced squamous NSCLC should talk to their oncologist about what's actually approved and available to them today, and ask specifically whether any ivonescimab or other bispecific antibody trials are enrolling in the U.S. if they want early access to this approach.